biotech

biotech Articles

Chimerix absolutely led the bears in Monday’s trading session on less-than-favorable results from a late-stage trial.
AnaptysBio has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
While there is certainly no guarantee that any of these hot biotech companies is bought, they each offer aggressive accounts big potential upside and have unique products and clinical possibilities...
The short interest data are out for the December 15 settlement date, and short interest continued to be mixed in these selected biotech stocks.
Biotech gets a lot of sustained attention, but some stocks still fall through the cracks, either due to recent failures or general lack of interest.
Good news for those who suffer from high levels of uric acid and from gout: the FDA has approved a new gout treatment.
pSivida was leading the bulls in Tuesday’s session on positive results from a late stage trial of Medidur.
Biotech looks set to close out 2015 as its worst performing year since 2008. But can we expect a better 2016 for this exciting sector?
As quickly as KaloBios Pharmaceuticals shares shot up, they are dropping after its newly named chief executive, Martin Shkreli, was arrested.
Advaxis has announced that the FDA has lifted the clinical hold on all of its Investigational New Drug (IND) applications for its three product candidates
Array BioPharma reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial.
Amgen is getting aggressive enough on its dividend payout that you might think the biotech giant is now just a Big Pharma stock.
Pacira Pharmaceuticals announced that it achieved an amicable resolution with the FDA for a lawsuit filed earlier this year that effectively lifts the restriction on its Exparel.
Neothetics Inc. (NASDAQ: NEOT) was absolutely crashed in Tuesday’s session after announcing top-line results from a late stage trial that fell short.
Spark Therapeutics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.